In the last trading session, 0.68 million shares of the CAMP4 Therapeutics Corp (NASDAQ:CAMP) were traded. Most recently the company’s share price was $1.92, and it changed around -$0.03 or -1.54% from the last close, which brings the market valuation of the company to $38.71M. CAMP currently trades at a discount to its 52-week high of $12.30, offering almost -540.63% off that amount. The share price’s 52-week low was $1.61, which indicates that the current value has risen by an impressive 16.15% since then.
CAMP4 Therapeutics Corp stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended CAMP as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight.
CAMP4 Therapeutics Corp (NASDAQ:CAMP) trade information
Instantly CAMP has showed a red trend with a performance of -1.54% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 2.0000 on recent trading dayincreased the stock’s daily price by 4.0%. The company’s shares are currently down -63.22% year-to-date, but still up 4.07% over the last five days. On the other hand, CAMP4 Therapeutics Corp (NASDAQ:CAMP) is -37.86% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $13.5, which translates to bulls needing to increase their stock price by 85.78% from its current value. Analyst projections state that CAMP is forecast to be at a low of $5 and a high of $18.
CAMP4 Therapeutics Corp earnings are expected to increase by 73.62% in 2025, but the outlook is positive 36.70% per year for the next five years.
CAMP Dividends
CAMP4 Therapeutics Corp’s next quarterly earnings report is expected to be released in June.
Fidelity Select Portfolios-Biotechnology Portfolio and Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND were the top two Mutual Funds as of Mar 31, 2025 . The former held 271.89 shares worth $0.52 million, making up 1.35% of all outstanding shares. On the other hand, Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND held roughly 233.7 shares worth around $0.45 million, which represents about 1.16% of the total shares outstanding.
